LENSAR entered this earnings day riding a sharp short term rebound, with the stock up about 48% over the past three months. However, the immediate reaction was muted. Shares slipped less than 1% to about US$8.20 by the close, which suggests investors are still processing what looked like a strong print rather than rushing for the exits.

The headline is simple. LENSAR just turned in its best quarter to date on profitability, with adjusted EBITDA of US$3.6 million and gross margin nearing 59%, powered by high margin recurring procedure revenue in its cataract surgery platform.

Love LENSAR's improving profitability profile but want more ideas with similar margins and recurring revenue strength? Check out the 18 high quality undiscovered gems.

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs Q2 2025): US$16.50m vs. US$13.94m (up about 18%)
• Net Income (Excl. Extra Items, Q2 2026 vs Q2 2025): US$3.54m vs. a loss of US$1.76m (returned to profit)
• Basic EPS (Q2 2026 vs Q2 2025): US$0.29 vs. a loss of US$0.15 per share (moved from loss to positive earnings per share)
• Gross Margin (Q2 2026 vs Q2 2025): approximately 59% including a US$1.1m tariff refund compared with a lower margin level in the prior year period (margin improved, supported by high recurring procedure revenue)

Prefer clean charts instead of a dense wall of earnings figures and margin tables? Get a full visual picture of LENSAR, with an at a glance view of its profitability and financials in the interactive company report for LENSAR.

LENSAR’s Bull Story Hinges On Recurring Procedure Scale

The bullish view on LENSAR centers on ALLY systems driving higher procedure volumes and a recurring revenue engine that supports stronger profitability. Q2 results go a fair way toward that. Recurring revenue reached US$13.7m and made up 83% of total revenue, while procedure revenue of US$10.2m and 58,682 procedures point to the utilization story starting to show through in the numbers. An installed base of about 215 ALLY systems out of 445 total, plus a backlog of 13 systems, supports the idea that placements are still building rather than stalling.

On profitability, adjusted EBITDA of US$3.6m and gross margin near 59% are in line with a thesis that recurring procedures can sustain a more profitable model. Even stripping out the US$1.1m tariff refund, the implied 52% margin suggests the core cataract platform is carrying more weight than in past periods.

Compare LENSAR's growing mix of high margin recurring procedures with how the stock actually trades after this earnings release. See whether Wall Street price targets reflect that profitability story in the consensus price target analysis for LENSAR.

LENSAR Bear Fears Soften, But Growth Gaps Remain

The bearish narrative on LENSAR argues that utilization and procedure mix are too fragile to support a recurring revenue model and that margin gains will be hard to sustain once one off benefits fade. This quarter pushes back on that to a degree. Procedure revenue of US$10.2m on 58,682 procedures and recurring revenue at 83% of sales suggest the installed base is working rather than sitting idle.

However, bears focus heavily on milestones not yet hit. ALLY placements were 10 in the quarter, which keeps the installed base growing but not at a pace that clearly pressures larger rivals. International recovery is still a promise rather than a visible second leg. Gross margin at roughly 52% excluding the US$1.1m tariff refund also leaves little proof that mix alone can offset planned SG&A increases and potential pricing friction.

After a quarter that leans on tariff refunds and a high mix of recurring procedures, it is fair to ask whether LENSAR’s earnings quality and utilization trends are as robust as they look at first glance. Review the independent risk analysis for LENSAR which shows 3 important warning signs

Stay Ahead With Simply Wall St

If LENSAR’s mix of recurring procedure revenue and improving profitability metrics has your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch how future quarters shape the story. Once you decide to take a position, manage LENSAR alongside your other holdings in the Portfolio Command Center so you only see clear, focused updates that matter. For a longer term view, tap into the collective thinking of other investors through the Community and see how sentiment and thesis points evolve over time. This way you spot potential catalysts and risks early and give yourself a better chance to stay ahead of the market.

Seeking Alternatives Beyond LENSAR Today

Fresh ideas move quickly. Some stocks build quiet breakout momentum while others get caught dropping just as attention shifts. Scan these under the radar opportunities before the crowd arrives and act now.

• Spot cash rich compounders early by reviewing the curated list of solid balance sheet and fundamentals stocks (50 results) that highlights companies with resilience and fundamentals that can keep a portfolio grounded when sentiment swings.
• Consider potential yield plus price momentum by checking out 10 dividend fortresses that focuses on stocks where income strength and balance sheet support work together while they are still under followed.
• Explore future facing infrastructure trends by scanning 38 power grid technology and infrastructure stocks and see which companies are positioned for grid upgrades and electrification while they remain under the radar for now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.